2015•Clinical Lymphoma Myeloma & LeukemiaOpen access

Evaluation of Clinical and Biological Prognostic Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPI Study

Carlos Panizo, A Rodriguez, Gonzalo Gutiérrez, Francisco Javier Díaz Pernas, Eva González‐Barca, Raquel de Oña, Carlos Grande, Juan‐Manuel Sancho, María Flor García-Álvarez, Blanca Sánchez‐González, Francisco Javier Peñalver, Jimena Cannata, Manuel Espeso, M.J. Requena, Santiago Gardella, Soledad Durán, Ana Pilar González, Ana Alfonso Piérola, Marı́a Dolores Caballero

Open full text 7 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rituximab, Diffuse large B-cell lymphoma, Medicine, Oncology, Lymphoma, Internal medicine, Chemotherapy, Refractory (planetary science)